PT. Selatox Bio Pharma is a 100% owned subsidiary of Daewoong Pharmaceutical in Korea, which develops and produces biological products such as botulinum toxin and aims to expand globally. Daewoong Pharmaceutical is one of the leading pharmaceutical companies in Korea with a sales revenue of over 1.3 billion USD. The company is actively focusing on research and development as well as global expansion. Daewoong Pharmaceutical invests more than 15% of its revenue into research and development and has over 100 research and business partners worldwide. We plan to establish a production base for botulinum toxin products in Indonesia as a global bio hub strategic base and target the global market with better accessibility and services through the development and production of competitive new products. We have a vision of becoming a “2030 leading global biopharmaceutical company.”
Selatox Research & Development Team is responsible for product development and regulatory approvals using botulinum strains and toxins. The team is composed of three parts; the Formulation Research Team, which utilizes toxin proteins; the Animal Testing Team, which conducts potency evaluations of raw materials and products; and the Regulatory Affairs Team, which handles product approval applications, modifications, and consultations.